Followers | 37 |
Posts | 3832 |
Boards Moderated | 0 |
Alias Born | 07/08/2002 |
Saturday, October 23, 2021 9:33:23 AM
Let's look at what you wrote:
"Why should any drug fit for public consumption be "surprisingly safe." Shouldn't the drug, any drug fit for public consumption be safe?
What results clinically prove that Leronlimab is actually beneficial?
Dr. Scott Kelly said "anecdotes don't get out of bed," but anecdotes aren't clinically recorded results from a study are they?"
First of all, Leronlimab has not been approved by the FDA, therefore it is not classified as anything. It is not fit for "MASS" public consumption. It is only EIND acceptable. In other words, take it at your own risk or better yet, it is the last thing one should take, called RTT - Right to try.
Now, the results have only been recorded in RTT cases and if that sick/dying patient only was suffering from COVID, that patient experienced the Lazarus syndrome after 3-6 days and went home. Yes, that is an anecdote, a living-breathing-surviving anecdote. Is this not beneficial?
I would not admonish someone for saying that Leronlimab works. The standard definition of "what results clinically prove that Leronlimab is actually beneficial?"Well, there are many Lazarus-types walking around. They have been described in newspaper reports - they arose from their deathbed! An unapproved drug that saves lives, yet an unapproved drug will not have verifiable results because it is unapproved. So, this is where that paradigm, "both ways" kicks in.
There are at least 70,000 reasons why people have invested in Leronlimab. They have invested in basically, an anecdote because it is an unapproved drug. Yet it is the only one that consistently turns the walking dead into the replenished.
Clinically proven results do not matter. Would I take Leronlimab if I were dying even if it's an anecdote? I'm sure you know the answer.
Recent CYDY News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/11/2024 01:00:15 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 10/01/2024 09:15:42 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 09/30/2024 09:01:16 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/13/2024 04:15:06 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 09/07/2024 12:44:56 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 09/07/2024 12:42:22 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 08/15/2024 09:21:30 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 07/22/2024 01:00:58 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/09/2024 09:17:48 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/09/2024 09:16:28 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 07/09/2024 09:16:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/09/2024 12:46:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 09:15:10 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 06/03/2024 09:10:56 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:17:30 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:16:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:09:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 02:30:20 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:16:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:15:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/22/2024 10:16:11 PM
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • CBDL • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM